Nivolumab vs Sars-Cov-2 Virus Spike Protein

## Nivolumab vs Sars-Cov-2 Virus Spike Protein: Overview

This comparison examines the pharmacological differences between **Nivolumab** and **Sars-Cov-2 Virus Spike Protein**.

## Mechanism of Action

**Nivolumab**: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

## Pharmacokinetics

**Half-life**: Nivolumab — 27 days; Sars-Cov-2 Virus Spike Protein — N/A.

## Chemical Properties

**Type**: Nivolumab — Antibody; Sars-Cov-2 Virus Spike Protein — Vaccine component.